DelveInsight’s “Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chemotherapy Induced Neutropenia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chemotherapy Induced Neutropenia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chemotherapy Induced Neutropenia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chemotherapy Induced Neutropenia: An Overview
Neutrophils belong to the phagocyte system and represent the first cellular components of the inflammatory response and key components of innate immunity. Most healthy people have an absolute neutrophil count (ANC) of approximately 1,500–7000/mmᶾ of blood. When levels of neutrophils drop below 1,500/mmᶾ of blood, the condition is called neutropenia.
As a consequence of systemic cancer treatment, neutropenia is the most common and potentially serious hematological complication in cancer patients undergoing chemotherapy. Neutropenia of this etiology is commonly known as chemotherapy-induced neutropenia (CIN).
Chemotherapy-induced neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. The risk of infection in CIN patients ranges between 10% and 50% for patients with solid tumors and more than 80% for hematological malignancies.
The initial evaluation of a patient with CIN includes medical history, initial physical assessments, urinalysis, sputum, stool cultures, laboratory tests—including complete blood cell counts with differential leukocyte and platelet counts—are needed to determine ANC and neutropenia severity.
The timing of the drop in neutrophil levels is based on the type or dose of chemotherapy. Neutrophil counts generally start to drop about a week after each round of chemotherapy begins.
Chemotherapy Induced Neutropenia Market Key Facts
-
In the 7MM, the total estimated number of cancer patients on chemotherapy was 1,816,200 in 2021.
-
In 2021, the highest number of cancer patients on chemotherapy were accounted by the US, making up to ~705,300 cases. Japan ranked second among 7MM countries with ~322,300 cancer patients on chemotherapy in 2021.
-
In 2021, Japan accounted for ~154,500 cases of CIN, which was the second-highest after the US among 7MM countries.
-
Tthere were ~147,000 cases at intermediate-high risk for CIN, and ~63,000 cases at low risk for CIN in Germany, in 2021.
-
The CIN cases include various cancers such as breast, lung, ovarian, AML, lymphoma and other cancers. Out of all cancers, in 2021, the highest CIN cases was from breast cancer i.e. ~205,100 cases. Furthermore, ~4,600 CIN cases in AML were the lowest among all cancers, in the 7MM.
-
In 2021, the total number of cases of CIN in the 7MM was ~916,300.
Chemotherapy Induced Neutropenia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chemotherapy Induced Neutropenia pipeline therapies. It also thoroughly assesses the Chemotherapy Induced Neutropenia Market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Chemotherapy Induced Neutropenia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chemotherapy Induced Neutropenia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chemotherapy Induced Neutropenia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chemotherapy Induced Neutropenia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chemotherapy Induced Neutropenia Epidemiology, Segmented as –
-
Total Number of Patients on Chemotherapy in the 7MM [2019–2032]
-
Risk-specific Chemotherapy Patient Pool for CIN in the 7MM [2019–2032]
-
Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the 7MM [2019–2032]
Chemotherapy Induced Neutropenia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chemotherapy Induced Neutropenia market or expected to be launched during the study period. The analysis covers the Chemotherapy Induced Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chemotherapy Induced Neutropenia drugs based on their sale and market share.
The report also covers the Chemotherapy Induced Neutropenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chemotherapy Induced Neutropenia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chemotherapy Induced Neutropenia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market
Chemotherapy Induced Neutropenia Therapeutics Analysis
The management of Chemotherapy Induced Neutropenia involves two main strategies: modification of the chemotherapy regimen and/or the use of growth factors. The optimal strategy for the management of CIN is prevention. In the management of CIN, myeloid growth factors (MGFs), including G-CSF and granulocyte macrophage-colony stimulating factor (GM-CSF), are used in clinical practice to reduce the risk of febrile neutropenia (FN) and its complications. Currently there are four recombinant G-CSF formulations: filgrastim (nonglycosylated), lenograstim (glycosylated), pegfilgrastim (filgrastim in pegylated version), and lipefilgrastim (filgrastim in glycosylate version).
Current treatment for neutropenia associated with chemotherapy is limited to two approved biologics such as Neupogen (filgrastim) and Neulasta (pegfilgrastim) and their biosimilars. Biosimilar versions exist for filgrastim and pegfilgrastim. The pegylated version differs for the different plasma half-life, much longer than the non-pegylated version (3–4 h), and allows a single administration of the drug per chemotherapy cycle. In September 2022, Hanmi Pharmaceuticals announced that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has obtained marketing approval from the US Food and Drug Administration.
Several major pharma and biotech companies are developing therapies for Chemotherapy Induced Neutropenia. Currently, Enzychem Lifesciences is leading the therapeutics market with its Chemotherapy Induced Neutropenia drug candidates in the most advanced stage of clinical development.
Chemotherapy Induced Neutropenia Companies Actively Working in the Therapeutics Market Include
-
Aileron Therapeutics
-
Amgen
-
BeyondSpring Pharmaceuticals
-
Cellerant Therapeutics
-
Enzychem Lifesciences Corporation
-
Evive Biotech
-
G1 Therapeutics
-
Kyowa Hakko Kirin Co., Ltd.
-
Myelo Therapeutics GmbH
-
Spectrum Pharmaceuticals
-
Teva B.V.
And Many Others
Emerging and Marketed Chemotherapy Induced Neutropenia Therapies Covered in the Report Include:
-
ALRN-6924: Aileron Therapeutics
-
EC-18: Enzychem Lifesciences Corporation
-
Myelo001: Myelo therapeutics
-
Plinabulin: BeyondSpring Pharmaceuticals
-
F-627 (Ryzneuta): Evive Biotech
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chemotherapy Induced Neutropenia Competitive Intelligence Analysis
4. Chemotherapy Induced Neutropenia Market Overview at a Glance
5. Chemotherapy Induced Neutropenia Disease Background and Overview
6. Chemotherapy Induced Neutropenia Patient Journey
7. Chemotherapy Induced Neutropenia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chemotherapy Induced Neutropenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy Induced Neutropenia Unmet Needs
10. Key Endpoints of Chemotherapy Induced Neutropenia Treatment
11. Chemotherapy Induced Neutropenia Marketed Therapies
12. Chemotherapy Induced Neutropenia Emerging Drugs and Latest Therapeutic Advances
13. Chemotherapy Induced Neutropenia Seven Major Market Analysis
14. Attribute Analysis
15. Chemotherapy Induced Neutropenia Market Outlook (In US, EU5, and Japan)
16. Chemotherapy Induced Neutropenia Companies Active in the Market
17. Chemotherapy Induced Neutropenia Access and Reimbursement Overview
18. KOL Views on the Chemotherapy Induced Neutropenia Market
19. Chemotherapy Induced Neutropenia Market Drivers
20. Chemotherapy Induced Neutropenia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Subarachnoid Hemorrhage Market
“Subarachnoid Hemorrhage Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Subarachnoid Hemorrhage market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Subarachnoid Hemorrhage market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices